驱动基因在肺癌骨转移中的研究进展

Advanes of Driving Genes in Bone Metastases from Lung Cancer

骨是肺癌常见的血行转移部位之一,其发生率为30%~40%,好发于脊柱和躯干近端,包括脊柱、股骨、肋骨和胸骨等。肺癌骨转移患者中位生存期为6~10月,治疗后1年生存率为40%~50%。骨转移分子机制的研究对治疗具有重要的指导意义。研究显示肺癌原发灶和骨转移灶驱动基因表达存在异质性,然而肺癌驱动基因在肺癌骨转移中的作用以及对骨微环境的的影响机制尚不明确。本文就肺癌骨转移分子机制研究进展进行综述,着重对常见肺癌驱动基因在肺癌骨转移中的作用及对骨微环境的影响进行阐述。

The skeleton is a common hematogenous metastasis site in lung cancer. The incidence of bone metastases in lung cancer patients is 30%-40%. It mainly occurs in the spine and the proximal trunk, including the spine, femur, ribs and sternum. The median overall survival time of these patients is 6-10 months, and the 1-year survival rate is 40%-50%. Exploring the molecular mechanism of bone metastasis has important guiding significance for the treatment. Some studies showed that driving genes in primary lesion and bone metastases sites are heterogeneous. However, it is still uncertain that the role of lung cancer driving genes in bone metastasis and their impact on bone microenvironment. This paper reviews the recent advances of molecular mechanisms of bone metastasis from lung cancer, focuses on the role of common driving genes in lung cancer bone metastasis and its effect on bone microenvironment.